Gordon Stephen 4

4 · TransMedics Group, Inc. · Filed May 31, 2024

Insider Transaction Report

Form 4

Period: 2024-05-29

TransMedics Group, Inc.TMDX

Gordon Stephen

Chief Financial Officer

Transactions

Sale
Common Stock
2024-05-29$141.27/sh−2,000$282,540→ 21,299 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-29−5,000→ 23,167 total
Exercise: $13.28Exp: 2032-02-22→ Common Stock (5,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-29−1,000→ 17,690 total
Exercise: $83.14Exp: 2034-02-23→ Common Stock (1,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-29−5,000→ 15,022 total
Exercise: $66.10Exp: 2033-02-20→ Common Stock (5,000 underlying)
Sale
Common Stock
2024-05-29$141.06/sh−9,345$1,318,206→ 29,954 total
Exercise/Conversion
Common Stock
2024-05-29$66.10/sh+5,000$330,500→ 39,299 total
Sale
Common Stock
2024-05-29$141.80/sh−8,655$1,227,279→ 21,299 total
Exercise/Conversion
Common Stock
2024-05-29$16.14/sh+2,000$32,280→ 23,299 total
Exercise/Conversion
Common Stock
2024-05-29$38.46/sh+5,000$192,300→ 28,299 total
Exercise/Conversion
Common Stock
2024-05-29$13.28/sh+5,000$66,400→ 33,299 total
Exercise/Conversion
Common Stock
2024-05-29$83.14/sh+1,000$83,140→ 34,299 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-29−2,000→ 84 total
Exercise: $16.14Exp: 2030-02-27→ Common Stock (2,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-29−5,000→ 17,477 total
Exercise: $38.46Exp: 2031-02-24→ Common Stock (5,000 underlying)

Footnotes (8)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $140.75 to $141.4025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $140.445 to $141.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $141.45 to $142.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The option is fully vested.
[F5]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025.
[F6]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.
[F7]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 23, 2028.
[F8]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027.

Documents

1 file

4
ownership.xmlPrimary
4